Insulin long-acting(Hanmi Pharmaceutical)(Insulin long-acting(Hanmi Pharmaceutical)) - 药物靶点：INSR_在研适应症：糖尿病_专利_临床

概要

基本信息

药物类型

生物类似药、激素

别名

LAPS-Insulin(Hanmi Pharmaceutical)、LAPSInsulin(Hanmi Pharmaceutical)、LAPSInsulin115

+ [6]

靶点

INSR

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

糖尿病

非在研适应症

胰岛素依赖型糖尿病21型糖尿病2型糖尿病

原研机构

Hanmi Pharmaceutical Co., Ltd.

在研机构

German Diabetes Center Mergentheim

ProSciento, Inc.

非在研机构

Hanmi Pharmaceutical Co., Ltd.

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 4868

Sequence Code 4857

关联

6

项与 Insulin long-acting(Hanmi Pharmaceutical) 相关的临床试验

NCT03332836 / Terminated临床1期

A Phase 1, Multiple Ascending Dose, Glucose Clamp Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM12460A Compared to Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.

开始日期2017-10-25

申办/合作机构

Hanmi Pharmaceutical Co., Ltd.

NCT03330314 / Completed临床1期

An Open Label, Fixed-Sequence, Glucose Clamp Study to Compare Molar Potency of HM12460A and Insulin Glargine in Healthy Subjects

This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.

开始日期2017-10-24

申办/合作机构

Hanmi Pharmaceutical Co., Ltd.

NCT03332849 / Unknown status临床1期

A Phase 1, Multiple Ascending Dose Glucose Clamp Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470 in Comparison to Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes Mellitus

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus

开始日期2015-07-28

申办/合作机构

Hanmi Pharmaceutical Co., Ltd.

100 项与 Insulin long-acting(Hanmi Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与 Insulin long-acting(Hanmi Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与 Insulin long-acting(Hanmi Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

18

项与 Insulin long-acting(Hanmi Pharmaceutical) 相关的文献（医药）

2023-03-01·Journal of Veterinary Internal Medicine

Erratum for “Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs”

2023-01-01·Gastroenterology report

Comparison of clinical efficacy between LAPS and ALPPS in the treatment of hepatitis B virus-related hepatocellular carcinoma.

Article

作者: Feng, Shiting ; Li, Shaoqiang ; Kuang, Ming ; Liao, Junbin ; Shen, Shunli ; Tan, Jiehui ; Chen, Zebin ; Xie, Wenxuan

BackgroundInsufficient post-operative future liver remnant (FLR) limits the feasibility of hepatectomy for patients. Staged hepatectomy is an effective surgical approach that can improve the resection rate of hepatocellular carcinoma (HCC). This study aimed to compare the safety and efficacy of laparoscopic microwave ablation and portal vein ligation for staged hepatectomy (LAPS) and classical associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of hepatitis B virus (HBV)-related HCC.MethodsClinical data of patients with HBV-related HCC who underwent LAPS or ALPPS in our institute between January 2017 and May 2022 were retrospectively analysed.ResultsA total of 18 patients with HBV-related HCC were retrospectively analysed and divided into the LAPS group (n = 9) and ALPPS group (n = 9). Eight patients in the LAPS group and eight patients in the ALPPS group proceeded to a similar resection rate (88.9% vs 88.9%, P = 1.000). The patients undergoing LAPS had a lower total comprehensive complication index than those undergoing ALPPS but there was not a significant different between the two groups (8.66 vs 35.87, P = 0.054). The hypertrophy rate of FLR induced by ALPPS tended to be more rapid than that induced by LAPS (24.29 vs 13.17 mL/d, P = 0.095). The 2-year recurrence-free survival (RFS) was 0% for ALPPS and 35.7% for LAPS (P = 0.009), whereas the 2-year overall survival for ALPPS and LAPS was 33.3% and 100.0% (P = 0.052), respectively.ConclusionsLAPS tended to induce lower morbidity and FLR hypertrophy more slowly than ALPPS, with a comparable resection rate and better long-term RFS in HBV-related HCC patients.

2022-05-01·Research in Social and Administrative Pharmacy3区 · 医学

Modelling the use of variable rate intravenous insulin infusions in hospitals by comparing Work as Done with Work as Imagined

3区 · 医学

Article

作者: Crowley, Clare ; Lim, Rosemary H ; Iflaifel, Mais ; Iedema, Rick ; Greco, Francesca ; Ryan, Kath

BACKGROUNDVariable rate intravenous insulin infusions (VRIIIs) are widely used to treat elevated blood glucose (BG) in adult inpatients who are severely ill and/or will miss more than one meal. VRIIIs can cause serious harm to the patient if used incorrectly. Recent safety initiatives have embraced the Resilient Health Care (RHC) approach to safety by understanding how VRIIIs are expected to be used (Work as Imagined, 'WAI') and how it is actually used in everyday clinical care (Work as Done, 'WAD').OBJECTIVESTo systematically compare WAI and WAD and analyse adaptations used in situ to develop a model explaining VRIII use.METHODSA qualitative observational study video-recording healthcare practitioners using VRIII. The video data were transcribed and inductively coded to develop a hierarchical task analysis (HTA) to represent WAD. This HTA was compared with a HTA previously developed to represent WAI. The comparison output was used to develop a model of VRIII use.RESULTSWhile many of the tasks in the WAD HTA were aligned with the tasks presented in the WAI HTA, some important ones did not. When misalignment was observed, permanent adaptations (e.g. signing as a witness for a changed VRIII's rate without independently verifying whether the new rate was appropriate) and temporary workarounds (e.g. not administering intermediate-acting insulin analogues although the intermediate-acting insulin prescription was not suspended) were the most frequently observed adaptations. The comparison between WAI and WAD assisted in developing a model of VRIII use. The model shed light on strategies used to imagine everyday work (e.g. incident reports, VRIII guidelines), how everyday work was accomplished (e.g. context-dependent adaptations) and how these contributed to both successful and unsuccessful outcomes.CONCLUSIONSThis study provided in-depth understanding of the tasks required while using VRIIIs, and responses and adaptations needed to achieve safer care in a complex environment.

100 项与 Insulin long-acting(Hanmi Pharmaceutical) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Insulin long-acting(Hanmi Pharmaceutical)	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	美国	Hanmi Pharmaceutical Co., Ltd.	2012-12-20
糖尿病	临床前	德国	German Diabetes Center Mergentheim	2017-07-13
糖尿病	临床前	美国	ProSciento, Inc.	2017-07-13
胰岛素依赖型糖尿病2	临床前	美国	Hanmi Pharmaceutical Co., Ltd.	2015-07-28
1型糖尿病	临床前	韩国	Hanmi Pharmaceutical Co., Ltd.	2015-01-01
2型糖尿病	临床前	美国	Hanmi Pharmaceutical Co., Ltd.	2012-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EASD2015	N/A	-	-	HM12470	醖糧餘鹽壓廠範網範製(衊範構鬱網選網衊糧膚) = HM12470 did not acutely activate Akt or MAPK signaling pathways in human skeletal (hSkMC) and human vascular smooth muscle cells (hVSMC). However, upon long-term stimulation we could detect a significant Akt phosphorylation after 24 or 48 h exposure to HM12470 in hSkMC and hVSMC 積顧糧簾鬱製範繭襯艱 (積窪鑰積築艱鹽範壓積 ) 更多	积极	2015-09-15
				Regular insulin